ArticleInternational journal of microbiology2026
Characterization of Giant Myoviridae With Therapeutic Potential Against Grouper Pathogen,
Article in International journal of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of Giant Myoviridae With Therapeutic Potential Against Grouper Pathogen,International journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: In this study, a giant Myoviridae phage strain (ValKK1-20) was isolated from the sandy area of Kota Kinabalu, Sabah, Malaysia. The purified phage was characterized based on transmission electron microscopy (TEM) and its genomic DNA. The adsorption assay and one-step growth analyses were conducted to predict the critical phase of ValKK3 infection. Results: TEM analysis revealed that the phage possessed an elongated head with a sheathed tail, resembling members of the T4-like Myoviridae group. The genome characterization revealed that the phage belongs to T4 phage with a genome size 248,088 bp with 41.2% Conclusions: In conclusion, this study highlights the potential of selected phage ValKK3 as a biocontrol agent against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.